IL2 Imaging in Renal Transplantation

Status Active, not recruiting

Clinical Trial Summary

After renal transplantation 5 to 10% of patients experience allograft rejection. Rapid and accurate diagnosis is vital for implementation of additional immunosuppressive therapy. Currently, a renal biopsy is essential for the diagnosis of renal allograft rejection. However, this is an intervention associated with complications like bleeding, patient discomfort and hospital admission. Additionally, limited biopsy sample size may lead to false negative results. So, the introduction of a new non-invasive diagnostic tool for allograft rejection could have major implications for the care of renal transplant recipients. For the purpose of visualizing infiltrating T lymphocytes with positron emission tomography (PET), the tracer 18-Fluor-Interleukin-2 ([18F]FB-IL2) has been developed. The investigators hypothesized that a high correlation exists between [18F]FB-IL2 uptake and the extend of T cell infiltration into renal transplants with signs of rejection

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Kidney Transplant Rejection

Clinical Trial Details

NCT number	NCT03304223
Study type	Interventional
Source	University Medical Center Groningen
Contact
Status	Active, not recruiting
Phase	N/A
Start date	December 1, 2017
Completion date	December 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04491552` - TruGraf® Long-term Clinical Outcomes Study
Withdrawn	`NCT04560582` - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Completed	`NCT05747274` - SRDK0921_ Analytical Performance Study
Not yet recruiting	`NCT05482100` - CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Recruiting	`NCT06243289` - Improving KIdney Transplantation With Cellular Therapy Study
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed	`NCT04367610` - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Enrolling by invitation	`NCT06126380` - Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients	Phase 2
Terminated	`NCT05747053` - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Active, not recruiting	`NCT03714113` - Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients	N/A
Recruiting	`NCT04091984` - The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Recruiting	`NCT05335538` - TruGraf and TRAC In Pediatrics Study
Completed	`NCT03663335` - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients	Phase 2
Completed	`NCT03652402` - Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Recruiting	`NCT04773392` - Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR	Phase 4
Completed	`NCT03873623` - The TOGETHER Project - Kidney
Terminated	`NCT02974686` - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation	Phase 4
Terminated	`NCT04156204` - Immunosuppressant Medication Dosed Daily After Kidney Transplant	Early Phase 1
Completed	`NCT04601155` - Transition of Renal Patients Using AlloSure Into Community Kidney Care
Completed	`NCT03874299` - The TOGETHER Project - Kidney RNA-seq Validation